GERMANY - Private equity circles ratiopharm group

The structured sales process for the company begins today, with comprehensive documents to be sent out at the beginning of October. Potential bidders are expected to express their interest in the company in the coming weeks. VEM anticipates the completion of the transaction in the first quarter of 2010 at the earliest.

The ratiopharm group is a generics drugs manufacturer with a total turnover of EUR 1.7bn in 2008. ratiopharm consists partly of independently operating enterprises such as the smaller-scale generic producer CT Arzneimittel, or the Canadian Technilab group that was acquired in 2000. The vendor plans to sell the group as one, but may also consider selling the assets separately.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH
• Exits